|Articles|April 5, 2023
Pharma USA 2023: IRA Impact on Patients
Kevin Hagan, president and CEO of the PAN Foundation, spoke to PharmExec about the recent IRA changes to Medicare and how it positively effects patients.
Advertisement
Kevin Hagan, president and CEO of the PAN Foundation, participated on the Pharma USA 2023 panel "Post-Inflation Reduction Act: The continued need for patient assistance." Here he speaks to Pharmaceutical Executive about the IRA's impact on Medicare patients' affordability.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Sanofi Reaches Deals with ADEL for Novel Alzheimer’s Disease Drug, Dren Bio for B-cell Depletion Therapy
2
FDA Approves Enhertu Plus Perjeta as First-Line Therapy for HER2-Positive Metastatic Breast Cancer
3
Brent Saunders: Eyeing New Horizons
4
Lunit and Daiichi Sankyo Form Collaboration to Advance Research and Discovery for AI-Driven Biomarkers and Translational Oncology
5
